Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Voorraadrapport

Marktkapitalisatie: US$5.6b

Rhythm Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Rhythm Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -18.1%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 30%. De inkomsten zijn groeide met een gemiddeld percentage van 61% per jaar.

Belangrijke informatie

-18.09%

Groei van de winst

-11.90%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.04%
Inkomstengroei60.99%
Rendement op eigen vermogen-72.79%
Nettomarge-106.41%
Volgende winstupdate05 May 2026

Recente prestatie-updates uit het verleden

Recent updates

RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside

Analysts have nudged their blended price target for Rhythm Pharmaceuticals higher by $0.40 to $137.67, reflecting updated assumptions around revenue growth, profitability, discount rates, and future P/E multiples following recent research updates on Phase 3 trial outcomes and the commercial outlook for Imcivree and hypothalamic obesity. Analyst Commentary Recent research updates present a mixed but generally constructive picture, with several firms adjusting price targets following the EMANATE trial results and evolving expectations for Imcivree and hypothalamic obesity.

RYTM: Hypothalamic Obesity Expansion Will Drive Next Upside Phase

Rhythm Pharmaceuticals' fair value estimate has moved higher to $137.27 from $135.53, as analysts factor in recent price target revisions that balance EMANATE trial setbacks with continued focus on Imcivree commercial execution and next generation MC4R agonists. Analyst Commentary Street research around Rhythm Pharmaceuticals has shifted meaningfully following the EMANATE readout, with price targets adjusted both higher and lower as analysts weigh clinical risk against the commercial rollout of Imcivree and the potential of next generation MC4R agonists.

RYTM: Hypothalamic Obesity Approval And Launch Preparations Will Drive Next Upside Phase

The updated analyst model trims the blended price target for Rhythm Pharmaceuticals by about $4 to $135.53 as analysts factor in slightly lower revenue growth and margin assumptions, along with a higher projected future P/E multiple following recent EMANATE trial results and ongoing focus on Imcivree and hypothalamic obesity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals reflects a mixed but engaged view, with several firms adjusting price targets after EMANATE and other trial updates, as well as ongoing focus on Imcivree and hypothalamic obesity.

RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase

Analysts trimmed their blended price target for Rhythm Pharmaceuticals by a few dollars, reflecting slightly more conservative long-term revenue and margin assumptions, even as they continue to highlight the potential of IMCIVREE and the hypothalamic obesity opportunity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals shows a mix of enthusiasm about the IMCIVREE franchise and the hypothalamic obesity opportunity, along with some recalibration of long-term expectations that feeds into updated price targets.

Rare Obesity Leadership: Can Setmelanotide Scale Beyond the Clinic?

Rhythm Pharmaceuticals enters late February 2026 as the leader in "rare disease obesity," a niche that has remained remarkably insulated from the broader GLP-1 price wars. The company’s core asset, Setmelanotide , has seen rapid uptake in patients with Bardet-Biedl syndrome (BBS) and POMC deficiency, where traditional weight-loss drugs often fail.

RYTM: Stable Franchise Trends Will Support Next Phase Of Upside

Analysts have lifted their price target on Rhythm Pharmaceuticals to $145 from $140, citing slightly stronger than expected preannounced Q4 Imcivree revenue of about $57M and what they see as stable growth trends for the existing franchise. Analyst Commentary Recent commentary centers on how the preannounced Q4 Imcivree revenue of about US$57M feeds into expectations for Rhythm Pharmaceuticals' execution and valuation.

RYTM: March Review Decision Will Drive Next Phase Of Upside

Analysts lifted their price target on Rhythm Pharmaceuticals to US$145 from US$140, citing Q4 Imcivree revenues of about US$57 million coming in slightly ahead of expectations and their view that growth in the existing franchise remains stable. Analyst Commentary Recent commentary around Rhythm Pharmaceuticals focuses on how the latest Imcivree revenue update might influence expectations for growth, execution, and valuation.

RYTM: March Hypothalamic Obesity Decision Will Drive Next Phase Of Upside

Narrative Update Overview Analysts have inched their fair value estimate for Rhythm Pharmaceuticals higher to about $140 from $139, reflecting slightly higher Street price targets and expectations for steady Imcivree demand after a Q4 revenue preannouncement of roughly $57 million. The update also takes into account more cautious views on how much near term upside is left around upcoming label and trial milestones.

RYTM: March Obesity Decision And Prader Willi Data Will Shape Upside

Analysts have nudged their fair value estimate for Rhythm Pharmaceuticals higher to about US$139 per share from roughly US$138, reflecting recent price target increases from several firms, along with views that upcoming label expansion and clinical readouts are already largely reflected in the current share price. Analyst Commentary Recent Street research on Rhythm Pharmaceuticals shows a mix of enthusiasm around the commercial trajectory and upcoming label events, alongside some caution on how much of that story is already reflected in the share price.

RYTM: March FDA Obesity Decision Will Drive Next Phase Of Upside

Analysts have modestly lifted their fair value estimate for Rhythm Pharmaceuticals to approximately $138 from about $127, reflecting slightly higher long term revenue growth expectations and confidence in upcoming hypothalamic obesity label expansion, despite a recent downgrade on valuation concerns. Analyst Commentary Bullish analysts highlight that Rhythm's strong clinical execution in hypothalamic obesity and Bardet Biedl syndrome, along with robust year to date share performance, support a higher long term revenue trajectory and justify incremental price target increases.

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Dec 11

RYTM: March FDA Obesity Decision Will Drive Next Phase Of Share Upside

Analysts have edged their average price target for Rhythm Pharmaceuticals slightly higher to about $127 from roughly $126, reflecting confidence that strong Imcivree and bivamelagon data, along with anticipated hypothalamic obesity label expansion, can support continued growth. However, recent gains and a limited near term catalyst slate are tempering enthusiasm.

RYTM: December FDA Decision Will Drive Next Phase Of Share Upside

Rhythm Pharmaceuticals' analyst price target increased from $121.43 to $126.31, as analysts cite ongoing clinical progress and upcoming regulatory milestones that support further upside for the company’s shares. Analyst Commentary Analysts have recently weighed in on Rhythm Pharmaceuticals, offering both optimistic and cautionary perspectives based on the company's performance, upcoming catalysts, and valuation.

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 07
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

RYTM: Upcoming FDA Decision Will Drive Next Phase of Upside Momentum

Analysts have raised their price target for Rhythm Pharmaceuticals from $117.57 to $121.43 per share, citing improved profit margin projections and increased optimism about upcoming label expansions for setmelanotide. Analyst Commentary Recent updates from Street research provide a balanced view on Rhythm Pharmaceuticals, with both bullish and bearish perspectives influencing the company's outlook and valuation.

Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics

The analyst price target for Rhythm Pharmaceuticals was revised upward by $7 to reflect increased optimism from analysts about the company's potential label expansion and expected regulatory progress for setmelanotide in hypothalamic obesity. Analyst Commentary Recent updates from Street research indicate a positive reassessment of Rhythm Pharmaceuticals' prospects, particularly surrounding potential regulatory approval and expanding commercial opportunities for setmelanotide in hypothalamic obesity.

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

Rhythm Pharmaceuticals' analyst price target has increased from $114.86 to $118.36, as analysts cite encouraging clinical data and optimism about setmelanotide's approval prospects in hypothalamic obesity. These factors are driving the revised valuation.

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

The consensus price target for Rhythm Pharmaceuticals was raised to $114.86 as bullish analyst sentiment strengthened on strong Phase 2 obesity trial results, robust Imcivree sales, and optimistic expectations for regulatory milestones and long-term franchise durability. Analyst Commentary Bullish analysts highlight strong Phase 2 trial results for bivamelagon in hypothalamic obesity, demonstrating significant placebo-adjusted BMI reduction at multiple doses and exceeding expectations for efficacy over 14 weeks.

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Jul 10
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Jun 25
Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
User avatar

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

May 04
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 08

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25

Rhythm Pharmaceuticals: A Key Year Ahead

Dec 06

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Opbrengsten en kosten

Hoe Rhythm Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:RYTM Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 25190-202195167
30 Sep 25174-198176259
30 Jun 25156-188159251
31 Mar 25137-174149239
31 Dec 24130-265144146
30 Sep 24113-262139134
30 Jun 24102-261134130
31 Mar 2492-274127133
31 Dec 2377-185118135
30 Sep 2362-186111129
30 Jun 2344-182103116
31 Mar 2334-18195114
31 Dec 2224-18192109
30 Sep 2217-18187117
30 Jun 2213-17682123
31 Mar 225-16675117
31 Dec 213-7068104
30 Sep 211-626195
30 Jun 210-605490
31 Mar 210-564888
31 Dec 200-1344690
30 Sep 200-1324293
30 Jun 200-1344297
31 Mar 200-14642109
31 Dec 190-14137109
30 Sep 190-13336103
30 Jun 190-1153488
31 Mar 190-873161
31 Dec 180-742850
30 Sep 180-592438
30 Jun 180-531833
31 Mar 180-471330
31 Dec 170-381023
30 Sep 170-36822
30 Jun 170-32721
31 Mar 170-30621
31 Dec 160-29620
30 Sep 160-27618
30 Jun 160-23614
31 Mar 160-17510
31 Dec 150-1237
30 Sep 150-624

Kwaliteitswinsten: RYTM is momenteel verliesgevend.

Groeiende winstmarge: RYTM is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: RYTM is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 18.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van RYTM over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: RYTM is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 40.2% ).

Rendement op eigen vermogen

Hoge ROE: RYTM heeft een negatief Return on Equity ( -72.79% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/01 12:44
Aandelenkoers aan het einde van de dag2026/05/01 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Rhythm Pharmaceuticals, Inc. wordt gevolgd door 27 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Samantha Lynn SemenkowCitigroup Inc